Sylwia Dębska-Szmich

ORCID: 0000-0002-4599-3099
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • PI3K/AKT/mTOR signaling in cancer
  • Breast Cancer Treatment Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Genetic factors in colorectal cancer
  • Brain Metastases and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Advanced Breast Cancer Therapies
  • Colorectal Cancer Treatments and Studies
  • Estrogen and related hormone effects
  • Lung Cancer Treatments and Mutations
  • Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Multiple and Secondary Primary Cancers
  • Lung Cancer Research Studies
  • Neuroendocrine Tumor Research Advances
  • Bone health and treatments
  • Gastric Cancer Management and Outcomes
  • Medical Imaging Techniques and Applications
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Myasthenia Gravis and Thymoma
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • Cancer and Skin Lesions

Medical University of Lodz
2014-2023

Copernicus Memorial Hospital
2014-2023

RELX Group (Netherlands)
2019

Daejeon University
2019

National Academy of Medicine
2011-2017

Medical University of Warsaw
2017

National Institute of Oncology
2017

Masaryk Memorial Cancer Institute
2017

Lublin Oncology Center
2011-2012

Gdańsk Medical University
2011-2012

Patients with human epidermal growth factor receptor (HER)-2+ breast cancer are at particularly high risk for brain metastases; however, the biological basis is not fully understood. Using a novel HER-2 assay, we investigated correlation between quantitative expression in primary cancers and time to metastasis (TTBM) HER-2+ advanced patients treated trastuzumab.The study group included 142 consecutive who were administered trastuzumab-based therapy metastatic cancer. HER-2/neu gene copy...

10.1634/theoncologist.2011-0212 article EN The Oncologist 2012-01-01

Acanthosis nigricans is characterized by hyperpigmentation and hyperkeratosis of the skin or mucous membranes. Its malignant form associated with internal neoplasms, especially gastric adenocarcinoma (55–61%). Coexistence prostate cancer uncommon. In paraneoplastic type this dermatosis, lesions are characteristically more sudden onset severe than those in benign form. The efficacy various treatment strategies remains disappointing. We here report a case 66-year-old Caucasian patient...

10.1186/1471-2490-14-88 article EN cc-by BMC Urology 2014-11-15

There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression selected proteins primary tumor and risk BM patients with metastatic cancer (MBC).The study included 198 MBC (96 102 without BM). Using tissue microarrays derived from tumor, assessed by immunohistochemical ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, claudin 3 4.Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001),...

10.1016/j.breast.2013.08.011 article EN cc-by-nc-nd The Breast 2013-09-20

HER2 overexpression is an unfavorable prognostic factor in patients with breast cancer, but it also a target for the monoclonal antibody trastuzumab, which effective adjuvant and palliative settings. positivity inclusion criterion immunotherapy, not positive predictive factor, only half of benefit from treatment.The aim this study was to evaluate value HER3, PTEN phosphorylated (p-HER2) expression primary tumors treated trastuzumab or regimen.Immunohistochemical (IHC) analysis 3 antibodies...

10.5604/17322693.1151339 article EN PubMed 2015-05-05

Colorectal cancer is the second most frequently diagnosed malignancy and one of leading causes cancer-related death in Poland. Many reports different types have indicated that blood count parameters may serve as a source prognostic or predictive information.To assess association between these clinical outcome patients with advanced colorectal cancer.We retrospectively analysed database 295 treated first-line palliative chemotherapy at our institution from January 2008 to December 2012....

10.5114/pg.2018.78287 article EN cc-by-nc-sa Gastroenterology Review 2018-01-01

// Renata Duchnowska 1 , Jeff Sperinde 2 Bogumiła Czartoryska-Arłukowicz 3 Paulina Myśliwiec 4 John Winslow Barbara Radecka 5 Christos Petropoulos Regina Demlova 6 Marlena Orlikowska 7 Anna Kowalczyk 8 Istvan Lang 9 Ziółkowska 10 Sylwia Dębska-Szmich 11 Monika Merdalska 12 Aleksandra Grela-Wojewoda 13 Anton Żawrocki Wojciech Biernat Weidong Huang and Jacek Jassem Military Institute of Medicine, Warsaw, Poland Monogram Biosciences, Integrated Oncology, Laboratory Corporation America®...

10.18632/oncotarget.22027 article EN Oncotarget 2017-10-24

Hodgkin's lymphoma (HL) is one of the most curable malignant diseases in adults. However, HL patients have a higher risk developing second malignancies compared with general population. The population adult cancer survivors growing, thus, long‑term effects treatment, including secondary development, become an increasingly important concern field oncology. current study presents case female survivor who developed two within 29 years follow‑up. Furthermore, review literature was conducted,...

10.3892/ol.2014.2799 article EN Oncology Letters 2014-12-12

Bones are the most common metastatic site of relapse in breast cancer patients and prediction bone metastases (BM) risk might prompt developing preventive therapeutic strategies. The aim study was to correlate immunohistochemical (IHC) expression selected proteins primary with occurrence BM. We analyzed potentially associated BM tumors 184 (113 with- 71 without BM). Expression estrogen receptor (ER) tumor more compared those (74 vs. 45 % respectively, p = 0.0001), whereas this subset less...

10.1007/s12253-015-9957-0 article EN cc-by Pathology & Oncology Research 2015-06-11

// Renata Duchnowska 1 , Piotr J. Wysocki 2 Konstanty Korski 3 Bogumiła Czartoryska-Arłukowicz 4 Anna Niwińska 5 Marlena Orlikowska 6 Barbara Radecka 7 Maciej Studziński 8 Regina Demlova 9 Zi&oacute;łkowska 10 Monika Merdalska 11 Łukasz Hajac 12 Paulina Myśliwiec 13 Dorota Zuziak 14 Sylwia Dębska-Szmich 15 Istvan Lang 16 Małgorzata Foszczyńska-Kłoda Bożenna Karczmarek-Borowska 17 Anton Żawrocki 18 Kowalczyk Wojciech Biernat Jacek Jassem for the Central and East European Oncology Group...

10.18632/oncotarget.6375 article EN Oncotarget 2015-11-24

Trophoblastic differentiation in primary urothelial carcinoma of the prostate is extremely rare. An increased level β-subunit human chorionic gonadotropin serum detected approximately 30% cases. To our knowledge, concentration prostatic has never been reported and its clinical significance not evaluated yet.Here we present case a 67-year-old European patient who was admitted to hospital with hematuria, dysuria, enlarged painful testis. Ultrasonographic examination testis did reveal any focal...

10.1186/s13256-022-03458-9 article EN cc-by Journal of Medical Case Reports 2022-06-14

Fulvestrant is a selective oestrogen receptor (ER) down-regulator (SERD), which lacks partial agonistic properties characteristic for modulators (SERM). The drug indicated the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antioestrogen therapy. initial recommendation 250-mg dose was based on results clinical trials, revealed that fulvestrant non-inferior to anastrozole this indication. However, higher fulvestrant,...

10.5603/ocp.2017.0003 article EN Oncology in Clinical Practice 2017-01-01

In recent years, after a long standstill in pharmacotherapy of triple-negative breast cancer (TNBC), several new targeted agents have been registered for treatment patients with this neoplasm (pembrolizumab, olaparib, talazoparib, sacituzumab govitecan, and trastuzumab deruxtecan). The standard early TNBC operable primary tumors up to 2 cm negative lymph nodes is surgery followed by adjuvant chemotherapy possible radiotherapy. Patients higher local regional stages are candidates radical...

10.5603/ocp.96485 article EN Oncology in Clinical Practice 2023-12-05

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Dębska S, Kusińska R, Czernek U, et al. Prognostic value of expression intracellular and extracellular domains HER2 in patients with HER2-possitive breast cancer. Contemporary Oncology/Współczesna Onkologia. 2011;15(5):267-273. doi:10.5114/wo.2011.25654. APA Dębska, S., Kusińska, R., Czernek, U., Szydłowska-Pazera, K., Błasińska-Morawiec, M., & Dowgier-Witczak, I. (2011). Onkologia, 15(5), 267-273....

10.5114/wo.2011.25654 article EN cc-by-nc-sa Współczesna Onkologia 2011-01-01

AMA Dębska S, Potemski P. Structure and function of hormone receptors their crosstalk with growth factor receptors. Contemporary Oncology/Współczesna Onkologia. 2010;14(6):347-354. doi:10.5114/wo.2010.19149. APA Dębska, S., & Potemski, (2010). Onkologia, 14(6), 347-354. https://doi.org/10.5114/wo.2010.19149 Chicago Sylwia, Piotr Potemski. 2010. "Structure receptors". Onkologia 14 (6): Harvard pp.347-354. MLA Sylwia et al. receptors." vol. 14, no. 6, 2010, pp. Vancouver

10.5114/wo.2010.19149 article EN cc-by-nc-sa Współczesna Onkologia 2010-01-01

Wprowadzenie. Temat naturalnego planowania rodziny oraz fizjologii płodności kobiety jest poruszany w toku kształcenia na kierunkach medycznych. Dzięki temu studenci mogą poznać zalety i wady tej metody. Wiedza ta niezbędna, aby móc przyszłości pełni profesjonalnie przekazywać rzetelne informacje swoim pacjentom lub też stosować ją życiu osobistym.Cel pracy. Ocena wiedzy dotyczącej naturalnych metod wśród studentów kierunków medycznych Warszawskiego Uniwersytetu Medycznego.Materiał Badanie...

10.17219/pzp/64687 article PL Nursing and Public Health 2017-06-30
Coming Soon ...